

Eric Jonasch

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7632919/eric-jonasch-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

216
papers

8,650
citations

52
h-index

85
g-index

226
ext. papers

10,926
ext. citations

7.1
avg, IF

6.02
L-index

#	Paper	IF	Citations
216	Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022 , 20, 71-90	7.3	20
215	Patient-reported Experience of Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 Countries.. <i>European Urology Open Science</i> , 2022 , 37, 3-6	0.9	2
214	Sunitinib-Related Osteonecrosis of the External Auditory Canal: Case Report.. <i>Otolaryngology - Head and Neck Surgery</i> , 2022 , 1945998211071022	5.5	0
213	A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy.. <i>Science Translational Medicine</i> , 2022 , 14, eabm6420	17.5	0
212	VHL-P138R and VHL-L163R Novel Variants: Mechanisms of VHL Pathogenicity Involving HIF-Dependent and HIF-Independent Actions.. <i>Frontiers in Endocrinology</i> , 2022 , 13, 854365	5.7	
211	Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. <i>Nature Communications</i> , 2021 , 12, 6375	17.4	0
210	Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. <i>New England Journal of Medicine</i> , 2021 , 385, 2036-2046	59.2	41
209	Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermuted cancers. <i>Science Translational Medicine</i> , 2021 , 13, eabe6201	17.5	1
208	Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. <i>Lancet Oncology</i> , 2021 , 22, 1732-1739	21.7	6
207	Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease. <i>World Journal of Urology</i> , 2021 , 39, 2409-2415	4	7
206	Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma. <i>Cancers</i> , 2021 , 13,	6.6	6
205	Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. <i>Cancer Medicine</i> , 2021 , 10, 2341-2349	4.8	8
204	Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies. <i>Oncologist</i> , 2021 , 26, 476-482	5.7	5
203	Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. <i>Cancers</i> , 2021 , 13,	6.6	2
202	Inhibition of hypoxia-inducible factor-2β in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. <i>Nature Medicine</i> , 2021 , 27, 802-805	50.5	48
201	MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 30, 495-504	5.9	4
200	Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. <i>Cell</i> , 2021 , 184, 2988-3005.e16	56.2	15

199	Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 790.e17-790.e23	2.8	0
198	Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events 2021 , 9,		2
197	Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. <i>Nature Reviews Nephrology</i> , 2021 , 17, 245-261	14.9	67
196	Maternal and fetal outcomes in pheochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 13-21	18.1	13
195	Phase II study of the oral hypoxia-inducible factor 2 (HIF-2) inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 333-333	2.2	2
194	Somatic Copy Number Alterations and Associated Genes in Clear-Cell Renal-Cell Carcinoma in Brazilian Patients. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
193	The oral HIF-2 inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): Updated follow-up of a phase I/II study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 273-273	2.2	8
192	Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. <i>BJU International</i> , 2021 ,	5.6	2
191	Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. <i>Cancer</i> , 2021 , 127, 3957-3966	6.4	1
190	Gene Body Methylation of the Lymphocyte-Specific Gene Results in Its Overexpression and Regulates Cancer mTOR Signaling. <i>Molecular Cancer Research</i> , 2021 , 19, 1917-1928	6.6	2
189	Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 837.e9-837.e17	2.8	1
188	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit.. <i>Clinical Cancer Research</i> , 2021 ,	12.9	1
187	PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. <i>Nature Communications</i> , 2020 , 11, 2135	17.4	44
186	Chronic hepatitis C virus infection and genitourinary cancers: A case-control study. <i>Seminars in Oncology</i> , 2020 , 47, 165-167	5.5	
185	Macrophage HIF-1 β s an Independent Prognostic Indicator in Kidney Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 4970-4982	12.9	11
184	Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events. <i>British Journal of Cancer</i> , 2020 , 123, 898-904	8.7	14
183	Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. <i>Cancer Cell</i> , 2020 , 37, 371-386.e12	24.3	28
182	Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis. <i>Oncologist</i> , 2020 , 25, 252-258	5.7	38

181	Phase II study of the oral HIF-2 inhibitor MK-6482 for Von Hippel-Lindau disease-associated renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5003-5003	2.2	25
180	Phase I/II study of the oral HIF-2 inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 611-611	2.2	20
179	Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma. <i>JCO Oncology Practice</i> , 2020 , 16, e1264-e1271	2.3	5
178	NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 1160-1170	7.3	59
177	Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care. <i>Cancer Treatment Reviews</i> , 2020 , 89, 102062	14.4	7
176	Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. <i>ESMO Open</i> , 2020 , 5, e001073	6	
175	Phase II Study of Carfilzomib in Patients With Refractory Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 451-456	3.3	3
174	Hypoxia-Associated Factor (HAF) Mediates Neurofibromin Ubiquitination and Degradation Leading to Ras-ERK Pathway Activation in Hypoxia. <i>Molecular Cancer Research</i> , 2019 , 17, 1220-1232	6.6	6
173	Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e526-e533	3.3	3
172	Durable complete response in renal cell carcinoma clinical trials. <i>Lancet, The</i> , 2019 , 393, 2362-2364	4.0	2
171	SETD2 regulates the maternal epigenome, genomic imprinting and embryonic development. <i>Nature Genetics</i> , 2019 , 51, 844-856	36.3	101
170	Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). <i>Oncologist</i> , 2019 , 24, 491-497	5.7	17
169	Characterization of Hypoxia-associated Molecular Features to Aid Hypoxia-Targeted Therapy. <i>Nature Metabolism</i> , 2019 , 1, 431-444	14.6	76
168	Sources of Frustration Among Patients Diagnosed With Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019 , 9, 11	5.3	9
167	MTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma. <i>Oncogene</i> , 2019 , 38, 6211-6225	9.2	45
166	A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4501-4501	2.2	6
165	An open-label phase II study to evaluate PT2977 for the treatment of von Hippel-Lindau disease-associated renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS680-TPS680	2.2	7
164	NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 1278-1285	7.3	118

163	Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. <i>Communications Biology</i> , 2019 , 2, 386	6.7	54
162	Renal cell carcinoma brain metastasis with pseudoprogression and radiation necrosis on nivolumab after previous treatment with stereotactic radiosurgery: An illustrative case report and review of the literature. <i>Practical Radiation Oncology</i> , 2018 , 8, e262-e265	2.8	7
161	Interconnection: A qualitative analysis of adjusting to living with renal cell carcinoma. <i>Palliative and Supportive Care</i> , 2018 , 16, 146-154	2.5	3
160	VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. <i>Science</i> , 2018 , 361, 290-295	33.3	73
159	AKT isoform-specific expression and activation across cancer lineages. <i>BMC Cancer</i> , 2018 , 18, 742	4.8	18
158	Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2018 , 25, 783-793	5.7	32
157	A first-in-human phase 1 dose-escalation trial of the oral HIF-2a inhibitor PT2977 in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2508-2508	2.2	9
156	Homologous repair deficiency in VHL-mutated clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 585-585	2.2	3
155	Pilot study of dovitinib in patients with von Hippel-Lindau disease. <i>Oncotarget</i> , 2018 , 9, 23390-23395	3.3	6
154	BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation. <i>Neoplasia</i> , 2018 , 20, 32-43	6.4	6
153	Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1588-1593	2.2	29
152	Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial. <i>Lancet Oncology</i> , 2018 , 19, 1351-1359	21.7	35
151	Updates to the Management of Kidney Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 639-641	7.3	16
150	Examination of moderators of expressive writing in patients with renal cell carcinoma: the role of depression and social support. <i>Psycho-Oncology</i> , 2017 , 26, 1361-1368	3.9	14
149	Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 363-370	3.3	12
148	Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. <i>Journal of Urology</i> , 2017 , 198, 530-537	2.5	33
147	Incorporating New Systemic Therapies in Kidney Cancer Treatment. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 703-705	7.3	4
146	Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma. <i>Targeted Oncology</i> , 2017 , 12, 333-340	5	5

145	Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. <i>BJU International</i> , 2017 , 120, 782-792	5.6	42
144	Systematic Review: Perioperative Systemic Therapy for Metastatic Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2017 , 1, 57-64	0.6	6
143	Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2993-3001	2.2	112
142	Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017 ,	3.3	11
141	Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. <i>Cancer</i> , 2017 , 123, 4823-4831	6.4	56
140	Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 804-834	7.3	320
139	Recommendations for the Management of Rare Kidney Cancers. <i>European Urology</i> , 2017 , 72, 974-983	10.2	27
138	Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape. <i>Clinical Cancer Research</i> , 2017 , 23, 6686-6696	12.9	48
137	HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas. <i>Cancer Research</i> , 2017 , 77, 5313-5326	10.1	16
136	Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e205-e208	3.3	22
135	Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening. <i>BMC Genomics</i> , 2017 , 18, 678	4.5	18
134	Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma. <i>Oncotarget</i> , 2017 , 8, 42149-42158 ^{3,3}		3
133	Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience. <i>BJU International</i> , 2016 , 118, 264-71	5.6	15
132	Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review. <i>Current Medical Research and Opinion</i> , 2016 , 32, 741-7	2.5	11
131	Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. <i>European Urology</i> , 2016 , 69, 866-74	10.2	199
130	Autophagy degrades hypoxia inducible factors. <i>Molecular and Cellular Oncology</i> , 2016 , 3, e1104428	1.2	10
129	Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. <i>European Urology</i> , 2016 , 70, 348-57	10.2	82
128	Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US. <i>Journal of Medical Economics</i> , 2016 , 19, 462-8	2.4	7

127	Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 237.e19-267	2.8	19
126	The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial. <i>European Radiology</i> , 2016 , 26, 2798-807	8	25
125	Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death. <i>Modern Pathology</i> , 2016 , 29, 34-42	9.8	40
124	Fast clearance of lipid droplets through MAP1S-activated autophagy suppresses clear cell renal cell carcinomas and promotes patient survival. <i>Oncotarget</i> , 2016 , 7, 6255-65	3.3	28
123	Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. <i>BJU International</i> , 2016 , 117, 761-5	5.6	39
122	NCCN Evidence Blocks. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 616-9	7.3	32
121	Evaluation and management of pancreatic lesions in patients with von Hippel-Lindau disease. <i>Nature Reviews Clinical Oncology</i> , 2016 , 13, 537-49	19.4	52
120	Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 499-503	3.3	38
119	The use of spine stereotactic radiosurgery for oligometastatic disease. <i>Journal of Neurosurgery: Spine</i> , 2016 , 25, 239-47	2.8	27
118	Key considerations in the treatment of von Hippel-Lindau disease. <i>Future Oncology</i> , 2016 , 12, 1755-8	3.6	3
117	The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis. <i>Journal of Urology</i> , 2016 , 196, 678-84	2.5	20
116	Treatment of Relapsed Germ Cell Tumors: Time For Something New?. <i>Journal of Oncology Practice</i> , 2016 , 12, 449-50	3.1	
115	Dual Chromatin and Cytoskeletal Remodeling by SETD2. <i>Cell</i> , 2016 , 166, 950-962	56.2	128
114	Posttraumatic stress and depressive symptoms in renal cell carcinoma: association with quality of life and utility of single-item distress screening. <i>Psycho-Oncology</i> , 2015 , 24, 1477-84	3.9	14
113	Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2015 , 3, 1017-29	12.5	116
112	Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. <i>Modern Pathology</i> , 2015 , 28, 1225-35	9.8	17
111	Alternate sunitinib schedules in patients with metastatic renal cell carcinoma. <i>Annals of Oncology</i> , 2015 , 26, 1300-4	10.3	33
110	Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 166.e21-9	2.8	31

109	The PI3K/AKT Pathway and Renal Cell Carcinoma. <i>Journal of Genetics and Genomics</i> , 2015 , 42, 343-53	4	197
108	Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. <i>Journal of Urology</i> , 2015 , 194, 316-22	2.5	34
107	Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 805-19	4	4
106	First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 210-7	3.3	22
105	Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial. <i>Oncologist</i> , 2015 , 20, 1140-8	5.7	12
104	The Radiogenomic Risk Score: Construction of a Prognostic Quantitative, Noninvasive Image-based Molecular Assay for Renal Cell Carcinoma. <i>Radiology</i> , 2015 , 277, 114-23	20.5	49
103	Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinoma. <i>Cancer Research</i> , 2015 , 75, 316-29	10.1	26
102	Psychological states, serum markers and survival: associations and predictors of survival in patients with renal cell carcinoma. <i>Journal of Behavioral Medicine</i> , 2015 , 38, 48-56	3.6	10
101	Kidney cancer, version 3.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 151-9	7.3	166
100	Testicular Cancer, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 772-99	7.3	87
99	Kidney cancer: current and novel treatment options. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 679-81	7.3	
98	Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 427.e17-23	2.8	18
97	The impact of FGFR1 and FRS2 expression on sorafenib treatment in metastatic renal cell carcinoma. <i>BMC Cancer</i> , 2015 , 15, 304	4.8	13
96	Dysregulation of HIF2 and autophagy in renal cell carcinoma. <i>Molecular and Cellular Oncology</i> , 2015 , 2, e965643	1.2	3
95	Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomas. <i>Journal of Pathology: Clinical Research</i> , 2015 , 1, 212-24	5.3	8
94	Presurgical Therapy in Renal Cell Carcinoma 2015 , 335-343		
93	Genetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant protein. <i>Cancer Research</i> , 2014 , 74, 3127-36	10.1	18
92	Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. <i>Genome Research</i> , 2014 , 24, 241-50	9.7	124

91	Renal cell carcinoma. <i>BMJ, The</i> , 2014 , 349, g4797	5.9	311
90	Clear cell papillary renal cell carcinoma in patients with von Hippel-Lindau syndrome--clinicopathological features and comparative genomic analysis of 3 cases. <i>Human Pathology</i> , 2014 , 45, 1966-72	3.7	25
89	Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. <i>Cancer</i> , 2014 , 120, 1794-9	6.4	132
88	Genetic kidney cancer syndromes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 1347-55	7.3	19
87	Kidney cancer, version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 175-82	7.3	43
86	Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices. <i>Current Medical Research and Opinion</i> , 2014 , 30, 2041-50	2.5	32
85	Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States. <i>Current Medical Research and Opinion</i> , 2014 , 30, 2343-53	2.5	13
84	Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. <i>BJU International</i> , 2014 , 113, 376-82	5.6	37
83	Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomes. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014 , 37, 397-403	2.7	12
82	Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. <i>Journal of Urology</i> , 2014 , 191, 611-8	2.5	100
81	Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: a single institution experience. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 348-53	3.3	31
80	Partial nephrectomy in the setting of metastatic renal cell carcinoma. <i>Journal of Urology</i> , 2014 , 192, 36-42.5		8
79	Cadherin-11 in renal cell carcinoma bone metastasis. <i>PLoS ONE</i> , 2014 , 9, e89880	3.7	25
78	Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. <i>Lancet Oncology, The</i> , 2013 , 14, 1233-42	21.7	189
77	Molecular markers to predict response to therapy. <i>Seminars in Oncology</i> , 2013 , 40, 444-58	5.5	17
76	Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study. <i>European Urology</i> , 2013 , 63, 1122-7	10.2	67
75	Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013 , 36, 450-4	2.7	7
74	The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013 , 36, 620-4	2.7	43

73	Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas. <i>Clinical Cancer Research</i> , 2013 , 19, 2460-72	12.9	61
72	Radiofrequency ablation of renal tumours with clinical, radiographical and pathological results. <i>BJU International</i> , 2013 , 111, 997-1005	5.6	19
71	Contemporary approach to diagnosis and classification of renal cell carcinoma with mixed histologic features. <i>Chinese Journal of Cancer</i> , 2013 , 32, 303-11		15
70	Chemotherapy, Targeted Therapies, and Biological Therapies for Renal Cell Carcinoma 2013 , 713-725		
69	Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. <i>Clinical Cancer Research</i> , 2012 , 18, 3961-3971	12.9	113
68	A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. <i>European Urology</i> , 2012 , 62, 1013-9	10.2	117
67	Renal Tumors 2012 , 287-309		
66	An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays. <i>Proteome Science</i> , 2012 , 10, 56	2.6	48
65	State of the science: an update on renal cell carcinoma. <i>Molecular Cancer Research</i> , 2012 , 10, 859-80	6.6	121
64	Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease: case report. <i>Targeted Oncology</i> , 2012 , 7, 145-9	5	26
63	Agents that stabilize mutated von Hippel-Lindau (VHL) protein: results of a high-throughput screen to identify compounds that modulate VHL proteostasis. <i>Journal of Biomolecular Screening</i> , 2012 , 17, 572-80		21
62	Testicular cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 502-35	7.3	64
61	Ten years of progress in renal cell carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 690-3	7.3	8
60	Presurgical Therapy in Renal Cell Carcinoma 2012 , 241-247		
59	Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. <i>Journal of Urology</i> , 2011 , 185, 439-44	2.5	98
58	Clinical genomics of renal epithelial tumors. <i>Cancer Genetics</i> , 2011 , 204, 285-97	2.3	71
57	Emerging targeted therapies in metastatic renal cell carcinoma. <i>Current Clinical Pharmacology</i> , 2011 , 6, 189-98	2.5	11
56	Adjuvant and neoadjuvant therapy in renal cell carcinoma. <i>Current Clinical Pharmacology</i> , 2011 , 6, 144-50	2.5	10

55	Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre. <i>BJU International</i> , 2011 , 107, 741-747	5.6	25
54	A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. <i>BJU International</i> , 2011 , 108, 679-86	5.6	47
53	Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. <i>European Urology</i> , 2011 , 59, 10-5	10.2	83
52	Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. <i>European Urology</i> , 2011 , 60, 964-71	10.2	70
51	Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma. <i>Clinical Genitourinary Cancer</i> , 2011 , 9, 81-8	3.3	13
50	Have molecularly targeted therapies improved overall survival in renal cell carcinoma?. <i>Current Oncology Reports</i> , 2011 , 13, 153-6	6.3	1
49	Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. <i>Cancer</i> , 2011 , 117, 4958-65	6.4	45
48	Axitinib in the treatment of metastatic renal cell carcinoma. <i>Future Oncology</i> , 2011 , 7, 1247-53	3.6	27
47	Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis. <i>Modern Pathology</i> , 2011 , 24, 1470-9	9.8	82
46	Systemic therapy for sarcomatoid renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 913-20	3.5	7
45	Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy. <i>Journal of Clinical Oncology</i> , 2011 , 29, e203-5	2.2	15
44	Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. <i>Annals of Oncology</i> , 2011 , 22, 2661-2666	10.3	72
43	Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma. <i>Annals of Oncology</i> , 2010 , 21, 1599-1606	10.3	36
42	1661 DOES TARGETED THERAPY RESULT IN RELIABLE AND MEANINGFUL PRIMARY TUMOR DOWNSTAGING IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA?. <i>Journal of Urology</i> , 2010 , 183,	2.5	2
41	Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment. <i>Journal of Urology</i> , 2010 , 184, 1877-81	2.5	59
40	Long-term management of patients with metastatic renal cell carcinoma on targeted agents. <i>Expert Review of Anticancer Therapy</i> , 2010 , 10, 1883-9	3.5	7
39	Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. <i>Cancer</i> , 2010 , 116, 57-65	6.4	95
38	Targeted therapy for locally advanced renal cell carcinoma. <i>Targeted Oncology</i> , 2010 , 5, 113-8	5	5

37	Prognostic and predictive factors in the targeted therapy era: filling in the blanks. <i>Current Oncology Reports</i> , 2010 , 12, 143-5	6.3	
36	Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. <i>European Urology</i> , 2010 , 58, 819-28	10.2	73
35	Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. <i>Cancer</i> , 2010 , 116, 5219-25	6.4	97
34	Papillary renal cell carcinoma: radiologic-pathologic correlation and spectrum of disease. <i>Radiographics</i> , 2009 , 29, 741-54; discussion 755-7	5.4	102
33	Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. <i>Clinical Cancer Research</i> , 2009 , 15, 81-90	12.9	47
32	Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4076-81	2.2	145
31	Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 386-91	5.6	99
30	Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures. <i>Cancer</i> , 2009 , 115, 1859-66	6.4	27
29	Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma. <i>Cancer</i> , 2009 , 115, 2346-54	6.4	22
28	Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. <i>BJU International</i> , 2009 , 104, 456-60	5.6	45
27	Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. <i>Urology</i> , 2009 , 73, 337-41	1.6	28
26	Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. <i>Clinical Genitourinary Cancer</i> , 2009 , 7, 20-3	3.3	88
25	NCCN clinical practice guidelines in oncology: kidney cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009 , 7, 618-30	7.3	168
24	NCCN clinical practice guidelines in oncology: testicular cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009 , 7, 672-93	7.3	87
23	Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. <i>British Journal of Cancer</i> , 2008 , 98, 1336-41	8.7	55
22	Patterns of intervention for renal lesions in von Hippel-Lindau disease. <i>BJU International</i> , 2008 , 102, 940-56	5.6	28
21	A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. <i>Journal of Urology</i> , 2008 , 180, 867-72; discussion 872	2.5	50
20	Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. <i>Journal of Urology</i> , 2008 , 180, 94-8	2.5	131

19	A novel von Hippel-Lindau point mutation presents as apparently sporadic pheochromocytoma. <i>Cancer Investigation</i> , 2008 , 26, 642-6	2.1	1
18	Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal cancer tumorigenesis. <i>Cancer Biology and Therapy</i> , 2008 , 7, 1619-27	4.6	11
17	Adjuvant and neoadjuvant therapy in renal cell carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2008 , 14, 315-22	2.1	11
16	Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors. <i>Current Oncology Reports</i> , 2008 , 10, 253-8	6.3	6
15	Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2008 , 113, 72-7	6.4	35
14	Presurgical therapy in metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2007 , 7, 73-83	3.5	12
13	Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience. <i>Urology</i> , 2007 , 69, 835-8	1.6	21
12	Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes. <i>Cancer</i> , 2006 , 106, 2143-7	6.4	14
11	Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. <i>Cancer</i> , 2006 , 107, 497-505	6.4	11
10	Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2006 , 107, 2254-61	6.4	35
9	Percutaneous radiofrequency ablation of renal tumors: technique, complications, and outcomes. <i>Journal of Vascular and Interventional Radiology</i> , 2005 , 16, 679-88	2.4	94
8	Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. <i>Melanoma Research</i> , 2005 , 15, 77-82	3.3	92
7	Port-site metastasis: the influence of biology. <i>European Urology</i> , 2005 , 47, 357-60	10.2	18
6	Lysophosphatidic acid production and action: validated targets in cancer?. <i>Journal of Cellular Biochemistry</i> , 2004 , 92, 1115-40	4.7	77
5	Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. <i>Blood</i> , 2003 , 102, 3829-36	2.2	125
4	Melanoma: what the primary care physician needs to know. <i>Primary Care Update for Ob/Gyns</i> , 2003 , 10, 51-59		
3	Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. <i>Oncologist</i> , 2001 , 6, 34-55	5.7	436
2	Melanoma vaccination: state-of-the-art and experimental approaches. <i>Expert Review of Anticancer Therapy</i> , 2001 , 1, 427-40	3.5	0

- 1 Ras- and Raf-induced down-modulation of non-muscle tropomyosin are MEK-independent. *Journal of Biological Chemistry*, **1998**, 273, 32182-6 5.4 31